Quality Management Optimizing HEDIS & STARSMedicare AdvantageApril 2, 2025

HEDIS measure: Statin Use in Persons with Diabetes (SUPD) 2025

Measure

This HEDIS® measure assesses the percentage of members with diabetes who take the most effective cholesterol lowering drugs to lower their risk of developing heart disease.

Refer to attachments to view full details

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

CarelonRx, Inc. is an independent company providing pharmacy benefit management services on behalf of the health plan.

Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc.
Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BC-CR-075413-24-CPN74739, MULTI-BCBS-CR-075415-24-CPN74739

ATTACHMENTS: HEDIS measure: Statin Use in Persons with Diabetes (SUPD) 2025 - Anthem Blue Cross and Blue Shield (pdf - 0.15mb), HEDIS measure: Statin Use in Persons with Diabetes (SUPD) 2025 - Anthem Blue Cross (pdf - 0.13mb)